BACKGROUND: White matter abnormalities may interfere with limbic-cortical balance and contribute to chronic depressive syndromes in the elderly. This study sought to clarify the relationship of SH to treatment response. We hypothesized that patients who failed to remit during a 12-week controlled treatment trial of escitalopram would exhibit greater SH burden than patients who remitted. METHODS: The participants were 42 non-demented individuals with non-psychotic major depression and 25 elderly comparison subjects. After a 2-week single blind placebo period, subjects who still had a Hamilton Depression Rating Scale (HDRS) of 18 or greater received escitalopram 10mg daily for 12 weeks. Remission was defined as a HDRS score of 7 or below for 2 consecutive weeks. FLAIR sequences were acquired on a 1.5 T scanner and total SH were quantified using a semi-automated thresholding method. RESULTS: The patient sample consisted of 22 depressed patients who achieved remission during the study and 20 depressed patients who remained symptomatic. ANCOVA, with age and gender as covariates, revealed that depressed subjects had greater total SH burden relative to non-depressed controls. Furthermore, patients who failed to remit following escitalopram treatment had significantly greater SH burden than both patients who remitted and elderly comparison subjects, whereas SH burden did not differ between depressed patients who remitted and elderly comparison subjects. LIMITATIONS: Patients were treated with a fixed dose of antidepressants and the index of SH is an overall measure that does not permit examination of the relationship of regional SH to treatment remission. DISCUSSION: SH may contribute to a "disconnection state" both conferring vulnerability to and perpetuating late-life depression.
RCT Entities:
BACKGROUND:White matter abnormalities may interfere with limbic-cortical balance and contribute to chronic depressive syndromes in the elderly. This study sought to clarify the relationship of SH to treatment response. We hypothesized that patients who failed to remit during a 12-week controlled treatment trial of escitalopram would exhibit greater SH burden than patients who remitted. METHODS: The participants were 42 non-demented individuals with non-psychotic major depression and 25 elderly comparison subjects. After a 2-week single blind placebo period, subjects who still had a Hamilton Depression Rating Scale (HDRS) of 18 or greater received escitalopram 10mg daily for 12 weeks. Remission was defined as a HDRS score of 7 or below for 2 consecutive weeks. FLAIR sequences were acquired on a 1.5 T scanner and total SH were quantified using a semi-automated thresholding method. RESULTS: The patient sample consisted of 22 depressedpatients who achieved remission during the study and 20 depressedpatients who remained symptomatic. ANCOVA, with age and gender as covariates, revealed that depressed subjects had greater total SH burden relative to non-depressed controls. Furthermore, patients who failed to remit following escitalopram treatment had significantly greater SH burden than both patients who remitted and elderly comparison subjects, whereas SH burden did not differ between depressedpatients who remitted and elderly comparison subjects. LIMITATIONS: Patients were treated with a fixed dose of antidepressants and the index of SH is an overall measure that does not permit examination of the relationship of regional SH to treatment remission. DISCUSSION: SH may contribute to a "disconnection state" both conferring vulnerability to and perpetuating late-life depression.
Authors: E Kramer-Ginsberg; B S Greenwald; K R Krishnan; B Christiansen; J Hu; M Ashtari; M Patel; S Pollack Journal: Am J Psychiatry Date: 1999-03 Impact factor: 18.112
Authors: G S Smith; C F Reynolds; B Pollock; S Derbyshire; E Nofzinger; M A Dew; P R Houck; D Milko; C C Meltzer; D J Kupfer Journal: Am J Psychiatry Date: 1999-05 Impact factor: 18.112
Authors: H S Mayberg; M Liotti; S K Brannan; S McGinnis; R K Mahurin; P A Jerabek; J A Silva; J L Tekell; C C Martin; J L Lancaster; P T Fox Journal: Am J Psychiatry Date: 1999-05 Impact factor: 18.112
Authors: Howard J Aizenstein; Alexander Khalaf; Sarah E Walker; Carmen Andreescu Journal: J Geriatr Psychiatry Neurol Date: 2013-12-30 Impact factor: 2.680
Authors: Adam M Brickman; Joel R Sneed; Frank A Provenzano; Ernst Garcon; Lauren Johnert; Jordan Muraskin; Lok-Kin Yeung; Molly E Zimmerman; Steven P Roose Journal: Psychiatry Res Date: 2011-06-16 Impact factor: 3.222
Authors: Lindsay W Victoria; George S Alexopoulos; Irena Ilieva; Aliza T Stein; Matthew J Hoptman; Naib Chowdhury; Matteo Respino; Sarah Shizuko Morimoto; Dora Kanellopoulos; Jimmy N Avari; Faith M Gunning Journal: J Affect Disord Date: 2018-09-11 Impact factor: 4.839
Authors: Sarah Shizuko Morimoto; Faith M Gunning; Dora Kanellopoulos; Christopher F Murphy; Sibel A Klimstra; Robert E Kelly; George S Alexopoulos Journal: Int J Geriatr Psychiatry Date: 2011-05-25 Impact factor: 3.485
Authors: Meenal J Patel; Carmen Andreescu; Julie C Price; Kathryn L Edelman; Charles F Reynolds; Howard J Aizenstein Journal: Int J Geriatr Psychiatry Date: 2015-02-17 Impact factor: 3.485